2023-508278-26-01Active, not recruitingPhase 1/2
A phase I clinical trial on combined (neo-)adjuvant intravenous plus intracranial administration of ipilimumab and nivolumab in recurrent glioblastoma.
Source: EU CTIS (euclinicaltrials.eu) · Last updated 3 Jun 2025
- Status (registry)
- Active, not recruiting
- Phase (registry)
- Phase 1/2
- Study type
- Interventional
- Enrollment
- 18 (estimated)
- First submitted
- 4 Dec 2023
- Start date
- 5 Apr 2024
- Lead sponsor
- UZ Brussel
- Diseases
- Glioblastoma
- EU CT number
- 2023-508278-26-01
What you commit to
- Study type: Interventional · Phase 1/2
- Planned participants: 18
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of EU CTIS (euclinicaltrials.eu). It describes the study design.
Sites (1)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| UZ Brussel | Jette | Belgium | Active, not recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.